Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 1/20 | 0.49 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.47 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.47 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.46 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | CCR8 | P51685 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.41 |
| ▸ | KHK | P50053 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14186225 | 1.00 | NMT1 (0.49) | NMT1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL8271848 | 1.00 | NMT1 (0.49) | NMT1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL20905651 | 0.84 | NMT1 (0.46) | NMT1ACVR1PRKCQPRKCDKIT | |
| SCHEMBL31045816 | 0.84 | ACVR1 (0.48) | NMT1ACVR1PRKCQPRKCDKIT | |
| SCHEMBL31658404 | 0.84 | NMT1 (0.48) | NMT1ACVR1PRKCQPRKCDKIT | |
| SCHEMBL14186226 | 0.83 | PRKCQ (0.50) | NMT1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL14186227 | 0.83 | NMT1 (0.52) | NMT1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL2244335 | 0.80 | ADRB1 (0.66) | NMT1ACVR1PRKCQPRKCDKARS1 | |
| SCHEMBL1026043 | 0.79 | ADRB1 (0.59) | NMT1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL30230278 | 0.79 | ADRB1 (0.59) | NMT1GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263628-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2011-10-27 | — | — | US | claimed |
| US-20080021028-A1 | N-Hydroxyamide Derivatives and Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-01-24 | — | — | US | claimed |
| US-20220162191-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2022-05-26 | — | — | US | disclosed |
| WO-2020182666-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2020-09-17 | — | — | WO | disclosed |
| US-8247437-B2 | N-hydroxyamide derivatives and use thereof | MERCK SERONO SA (CH) | 2012-08-21 | — | — | US | disclosed |
| US-20110263628-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2011-10-27 | — | — | US | disclosed |
| US-8008302-B2 | ((2S,3S) N,2-dihydroxy-5-methyl-3-{[4-(2-pyridinyl)-1-piperazinyl]carbonyl}hexanamide; for treatment and/or prevention of disorders related to autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, stroke, cancer, pre-term labor, endometriosis | MERCK SERONO SA (CH) | 2011-08-30 | — | — | US | disclosed |
| EP-1771421-B1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | SERONO LAB (CH) | 2009-04-29 | — | — | EP | disclosed |
| US-20080021028-A1 | N-Hydroxyamide Derivatives and Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-01-24 | — | — | US | disclosed |
| EP-1771421-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | Applied Research Systems ARS Holding N.V. (AN) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006010751-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263628-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | HNMT, HCAR2, HPGD | NMT1 46/4885GRIN2D 4498/4885GRIN3B 4150/4885 |
| US-20080021028-A1 | N-Hydroxyamide Derivatives and Use Thereof | HCAR2, HNMT, HPGD | NMT1 59/4885GRIN2D 4459/4885GRIN3B 4162/4885 |
| US-20220162191-A1 | SMALL MOLECULE MODULATORS OF IL-17 | IL17A, IL15, IL2 | NMT1 2796/4885GRIN2D 4763/4885GRIN3B 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.